



## Vascular Health

### How do we detect, treat and avoid cardiovascular problems, thrombosis and vascular disease?

7<sup>th</sup> December 2005, Royal Society of Medicine, London

Heart disease remains one of the biggest killers in the world. It is therefore imperative to continually develop novel and effective drugs, imaging capabilities, and devices to target this and vascular related problems. With continual reports highlighting the increase in cases of DVT and peripheral disorders it is essential that industry and academia collaborate to alleviate some of the bottlenecks in the market.

This event will provide a unique forum in which to access the region's academic brilliance, and gain detailed knowledge of the cutting-edge research and developments in the field of cardiovascular health. More specifically this event will consider: ♦ What are the biggest challenges in the development of new cardiovascular drug treatments? ♦ What are the latest technologies for improving imaging of structures and mechanisms? ♦ What is the future for vascular repair? ♦ What are the challenges faced regarding surgery and physical intervention in this market? and ♦ What opportunities are there for collaborative research and partnerships between the commercial and academic sectors?

**17.45- 18.15 Registration with tea and coffee**

**18.15- 18.30 Introduction to aims and objectives of LTN**  
**Jolyon White, Technology Consultant, LONDON TECHNOLOGY NETWORK**

**18.30- 20.00 Speaker presentations and Q&A**

**20.00- 21.00 Wine reception & buffet- networking opportunity & poster sessions from across London & the South East's universities showcasing the latest cardiovascular research**

#### **1. Introduction by the chair to the main issues in the field, focussing on cardiovascular drug development**

- ♦ Assessing the viability of preclinical animal models for cardiovascular safety pharmacology
- ♦ Examining the latest approaches to early cardiovascular drug screening - gauging the future needs
- ♦ How do these advancements aid the development of cardiovascular drugs e.g. for lipid modulation and blood pressure?
- ♦ Analysing early academic research which could alleviate some of the bottlenecks in the industry
- ♦ Highlighting the importance of industry and academia working together to reach a shared goal

**Chair: Professor Michael Marber**, Professor of Cardiology and Dean of St Thomas' Campus, Department of Cardiology, **King's College London**

#### **2. Evaluating the progress of cardiovascular imaging for drug development**

- ♦ Examining the current challenges of cardiovascular drug development and how imaging can help
- ♦ Analysing the technological developments to facilitate improved detection of disease and response to treatment
- ♦ Moving towards replacing invasive diagnostic tests with non-invasive imaging-derived biomarkers
- ♦ What are the major challenges-how can an industry/academic collaboration address these?

**Dr Philip Murphy**, Associate Director, Clinical Technology, Global Clinical Sciences, **Pfizer Global Research and Development**

#### **3. Assessing cardiovascular surgery and physical intervention techniques and equipment**

- ♦ What are the latest challenges with research into implanted devices
- ♦ Analysing the advantages and challenges associated with drug-eluting stents
- ♦ Exploiting technology from bench to bedside
- ♦ Evaluating the critical need for industry and academia to work together in this field

**Dr Peter Phillips**, Managing Director Cardiovascular Devices, **Lombard Medical**

#### **4. Highlighting the latest progress to aid vascular repair-where do we go from here?**

- ♦ Investigating the up-and-coming research and development in angiogenesis
- ♦ Addressing the current work being conducted to help with vascular disease
- ♦ What areas can academia help industry with to move forward?

**Professor Keith Channon**, Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, **University of Oxford**

#### **5. Question and answer session with the audience and speaker panel**

**All events are by INVITATION ONLY**



## **SPEAKER PROFILES**

### **Jolyon White - LONDON TECHNOLOGY NETWORK**

Jolyon received his PhD in Biochemistry from Nottingham University and has an MBA from the Open University. He then worked for two years in Quality Assurance for OTC pharmaceuticals and three years as a Research Fellow at Loughborough University. He was General Manager of a biotech company before joining Powderject for eight years where he was Business Development Manager extensively involved in international B2B sales and bio defence products.

### **Keith Channon - UNIVERSITY OF OXFORD, UK**

Keith is Professor of Cardiovascular Medicine at the University of Oxford and Honorary Consultant Cardiologist at the John Radcliffe Hospital, Oxford. He is an active Interventional Cardiologist, undertaking a high volume of complex coronary intervention and stent procedures. He has a number of current clinical research interests, including studies evaluating new stents and interventional devices, outcomes from coronary intervention and novel treatments including gene therapy in patients undergoing coronary artery bypass graft surgery. Keith also leads a basic science research group that focuses on basic mechanisms of endothelial function in vascular diseases. Keith is currently Chairman of the British Atherosclerosis Society, a member of the Council of the British Cardiac Society and a member of the British Society for Cardiovascular Research and the British Cardiac Intervention Society. He has acted as a Consultant and External Reviewer for the National Institute of Clinical Excellence, the Gene Therapy Advisory Committee of the Department of Health and the Medicines and Health Care Regulatory Authority. He plays an active role in Grants Committees in the British Heart Foundation and in the Fellowships Committee of the British Cardiac Society.

### **Michael Marber - KING'S COLLEGE LONDON**

Since 2005 Michael has been Dean of the St Thomas' Hospital Campus. He is currently Chairman of the British Society for Cardiovascular Research, a member of the Council of the British Cardiac Society, a member of the Physiological Sciences Panel of the Wellcome Trust and a member of the Cardiovascular Panel of the UK Research Assessment Exercise 2008. He also acts as a consultant and external reviewer for Health Technology Appraisals by the National Institute for Clinical Excellence and the Genetic Therapy Advisory Committee of the Department of Health. He is also a member of the Steering Group, and Chair of the Diagnostics Theme Grant Panel, of the Charitable Foundation of Guy's and St Thomas' Hospitals and is a member of the R&D Steering Group of the Guy's and St Thomas' NHS Foundation Trust. Michael serves on the Editorial Boards of the European Heart Journal, Journal of the American College of Cardiology, Dialogues in Cardiology, Heart and Metabolism, Basic Research in Cardiology and Current Vascular Pharmacology. His clinical research interests focus on the role of collaterals and ischaemic preconditioning in ischaemic heart disease and the care of patients with acute coronary syndromes.

### **Peter Philips - LOMBARD MEDICAL**

Peter became Managing Director in 1996 having joined the company during the previous year. He has been involved in the Healthcare sector in a variety of positions since 1985, spending four years as new product director at Surgicraft Ltd, prior to joining Anson Medical, which was acquired by Lombard Medical plc in 2001.

### **Philip Murphy - PFIZER GLOBAL RESEARCH AND DEVELOPMENT**

Philip is a Clinical Project Manager within the Global Clinical Technology group, Pfizer, UK. His remit is to develop novel technologies including imaging for application to drug development. Working across multiple therapeutic areas, his focus is on early development and especially translational methodologies. Previously he worked as an Applications Scientist for Marconi Medical Systems developing clinical MRI for very-high field MRI scanners. His background is primarily in MRI. He received a Ph.D. in Biophysics from the Institute of Cancer Research, UK. His research focused on developing novel clinical imaging and spectroscopy approaches to study tumour patho-physiology and response to therapy.

#### **See what participants said about previous LTN events:**

***"Thank you for the very valuable event"***

R. Suzuki, Associate Director, EISAI EUROPE

***"Excellent selection of speakers...excellent balance between industry and academic attendees"***

R. Kamugasha, Research Fellow, UNIVERSITY COLLEGE LONDON

***"I found the event extremely stimulating, it was good to get a different viewpoint and I will be making arrangements to visit some of the departments in the near future"***

M. Pullen, Chief Systems Architect, SYMBIAN

**All events are by INVITATION ONLY**




**LTN's Mission:**

**To help technology-intensive companies be more effective and efficient in their “knowledge acquisition” from London’s universities.**

Each month, London Technology Network brings together industrial and academic thought leaders in the most powerful new technologies, both on the stage and in the audience. LTN discussions identify common technology platforms shared across industries and disciplines, and explore how industry, government and academia can collaborate to introduce and exploit these technologies. Attendees build personal networks that foster efficient transfer of technology and drive down the cost and time to deliver new products to market. Through the London Innovation Relay Centre we also run a series of workshops to help London companies identify their technology needs and find suitable technology partners.

**HOW TO GET THERE**

This event will take place in the **The Royal Society of Medicine**, 1 Wimpole Street, London W1G 0AE  
Tel: 020 7290 2900. For further information go to <http://www.rsm.ac.uk/welcom/map.htm>



There is excellent tube and mainline station access. 1 Wimpole Street is located behind House of Fraser, off Oxford Street.

**By underground and train**

Bond Street and Oxford Circus underground stations are equidistant from the RSM, both with direct connections from Victoria, Marylebone, Kings Cross, Euston, Waterloo, Paddington and Liverpool Street.

**By road**

Wimpole Street is one way, approached from Henrietta Place.

Car Parks are located in Cavendish Square and Marylebone Lane, both five minutes away. There is a Master Park Car Park in Chandos Street just a few minutes away from Chandos House.